$DXCM
DEXCOM INC Stock $dxcm

$dxcm Overview Financials Valuation SEC Filings Company Website

2017 Q1 Form 10-Q Financial Statement

#000109355717000119 Filed on May 02, 2017

Income Statement

Concept	2017 Q1	2016 Q1
Revenue	$142.3M	$116.2M
YoY Change	22.46%	59.62%
Cost Of Revenue	$48.20M	$41.10M
YoY Change	17.27%	56.27%
Gross Profit	$94.10M	$75.10M
YoY Change	25.3%	61.51%
Gross Profit Margin	66.13%	64.63%
Selling, General & Admin	$86.40M	$62.10M
YoY Change	39.13%	57.61%
% of Gross Profit	91.82%	82.69%
Research & Development	$48.10M	$32.20M
YoY Change	49.38%	62.63%
% of Gross Profit	51.12%	42.88%
Depreciation & Amortization	$3.700M	$3.400M
YoY Change	8.82%	41.67%
% of Gross Profit	3.93%	4.53%
Operating Expenses	$134.5M	$94.30M
YoY Change	42.63%	59.29%
Operating Profit	-$40.40M	-$19.20M
YoY Change	110.42%	51.18%
Interest Expense	$500.0K	$100.0K
YoY Change	400.0%	-50.0%
% of Operating Profit
Other Income/Expense, Net	$400.0K	$0.00
YoY Change
Pretax Income	-$40.30M	-$19.20M
YoY Change	109.9%	48.84%
Income Tax	$1.400M	$0.00
% Of Pretax Income
Net Earnings	-$41.70M	-$19.20M
YoY Change	117.19%	48.84%
Net Earnings / Revenue	-29.3%	-16.52%
Basic Earnings Per Share	-$0.49
Diluted Earnings Per Share	-$0.49	-$233.9K
COMMON SHARES
Basic Shares Outstanding	84.82M shares	82.10M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q1	2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$181.1M	$106.5M
YoY Change	70.05%	27.09%
Cash & Equivalents	$153.5M	$77.90M
Short-Term Investments	$27.60M	$28.60M
Other Short-Term Assets	$17.00M	$7.500M
YoY Change	126.67%	97.37%
Inventory	$46.50M	$46.10M
Prepaid Expenses
Receivables	$85.90M	$67.30M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$330.5M	$227.4M
YoY Change	45.34%	55.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$123.4M	$65.90M
YoY Change	87.25%	84.59%
Goodwill	$11.40M	$3.700M
YoY Change	208.11%	15.63%
Intangibles		$2.000M
YoY Change		-23.08%
Long-Term Investments
YoY Change
Other Assets	$1.900M	$400.0K
YoY Change	375.0%	-33.33%
Total Long-Term Assets	$136.7M	$72.00M
YoY Change	89.86%	67.05%
TOTAL ASSETS
Total Short-Term Assets	$330.5M	$227.4M
Total Long-Term Assets	$136.7M	$72.00M
Total Assets	$467.2M	$299.4M
YoY Change	56.05%	58.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$17.90M	$21.50M
YoY Change	-16.74%	97.25%
Accrued Expenses	$77.60M	$40.30M
YoY Change	92.56%	79.91%
Deferred Revenue
YoY Change
Short-Term Debt	$75.00M	$0.00
YoY Change
Long-Term Debt Due		$1.700M
YoY Change		-29.17%
Total Short-Term Liabilities	$171.7M	$64.10M
YoY Change	167.86%	73.24%
LONG-TERM LIABILITIES
Long-Term Debt	$6.700M	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$17.70M	$4.100M
YoY Change	331.71%	105.0%
Total Long-Term Liabilities	$17.70M	$4.100M
YoY Change	331.71%	105.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$171.7M	$64.10M
Total Long-Term Liabilities	$17.70M	$4.100M
Total Liabilities	$189.4M	$68.20M
YoY Change	177.71%	67.57%
SHAREHOLDERS EQUITY
Retained Earnings	-$663.3M	-$574.6M
YoY Change	15.44%	12.51%
Common Stock	$942.3M	$806.0M
YoY Change	16.91%	22.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$277.8M	$231.2M
YoY Change
Total Liabilities & Shareholders Equity	$467.2M	$299.4M
YoY Change	56.05%	58.16%

Cashflow Statement

Concept	2017 Q1	2016 Q1
OPERATING ACTIVITIES
Net Income	-$41.70M	-$19.20M
YoY Change	117.19%	48.84%
Depreciation, Depletion And Amortization	$3.700M	$3.400M
YoY Change	8.82%	41.67%
Cash From Operating Activities	$300.0K	-$200.0K
YoY Change	-250.0%	-105.88%
INVESTING ACTIVITIES
Capital Expenditures	$22.90M	$11.50M
YoY Change	99.13%	43.75%
Acquisitions
YoY Change
Other Investing Activities	$1.500M	$300.0K
YoY Change	400.0%	-101.68%
Cash From Investing Activities	-$21.40M	-$11.20M
YoY Change	91.07%	-56.76%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$5.300M	$3.800M
YoY Change	39.47%	-30.91%
Debt Paid & Issued, Net	$0.00	$600.0K
YoY Change	-100.0%	0.0%
Cash From Financing Activities	$80.30M	$3.200M
YoY Change	2409.38%	-34.69%
NET CHANGE
Cash From Operating Activities	$300.0K	-$200.0K
Cash From Investing Activities	-$21.40M	-$11.20M
Cash From Financing Activities	$80.30M	$3.200M
Net Change In Cash	$59.00M	-$8.200M
YoY Change	-819.51%	-53.41%
FREE CASH FLOW
Cash From Operating Activities	$300.0K	-$200.0K
Capital Expenditures	$22.90M	$11.50M
Free Cash Flow	-$22.60M	-$11.70M
YoY Change	93.16%	154.35%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q1	dei	Amendment Flag AmendmentFlag	false
CY2017Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--03-31
CY2017Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017Q1	dei	Document Period End Date DocumentPeriodEndDate	2017-03-31
CY2017Q1	dei	Document Type DocumentType	10-Q
CY2017Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001093557
CY2017Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	86369677	shares
CY2017Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2017Q1	dei	Entity Registrant Name EntityRegistrantName	DEXCOM INC
CY2017Q1	dei	Trading Symbol TradingSymbol	DXCM
CY2016Q4	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	4500000	USD
CY2017Q1	dxcm	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	7800000	USD
CY2016Q4	dxcm	Clinical Trials ClinicalTrials	1100000	USD
CY2017Q1	dxcm	Clinical Trials ClinicalTrials	900000	USD
CY2017Q1	dxcm	Fair Value Assets Level3 Transfers Amount FairValueAssetsLevel3TransfersAmount	0	USD
CY2016Q4	dxcm	Financing Lease Obligation FinancingLeaseObligation	6700000	USD
CY2017Q1	dxcm	Financing Lease Obligation FinancingLeaseObligation	6700000	USD
CY2016Q4	dxcm	Pharmacy Rebates PharmacyRebates	8200000	USD
CY2017Q1	dxcm	Pharmacy Rebates PharmacyRebates	11000000	USD
CY2017Q1	dxcm	Recorded Unconditional Purchase Obligation Due Within One Year Maximum Term RecordedUnconditionalPurchaseObligationDueWithinOneYearMaximumTerm	P1Y
CY2017Q1	dxcm	Revenue Recognition Sales Returns Coverage Period RevenueRecognitionSalesReturnsCoveragePeriod	P30D
CY2016Q1	dxcm	Standard Product Warranty Accrual Charges To Costs And Expenses StandardProductWarrantyAccrualChargesToCostsAndExpenses	6200000	USD
CY2017Q1	dxcm	Standard Product Warranty Accrual Charges To Costs And Expenses StandardProductWarrantyAccrualChargesToCostsAndExpenses	5000000	USD
CY2017Q1	dxcm	Working Capital WorkingCapital	158800000	USD
CY2016Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	68100000	USD
CY2017Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	65400000	USD
CY2016Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	24500000	USD
CY2017Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	17900000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	101700000	USD
CY2017Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	85900000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1000000	USD
CY2017Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1300000	USD
CY2016Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	905700000	USD
CY2017Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	942300000	USD
CY2016Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5100000	shares
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3600000	shares
CY2016Q4	us-gaap	Assets Assets	402800000	USD
CY2017Q1	us-gaap	Assets Assets	467200000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	280000000	USD
CY2017Q1	us-gaap	Assets Current AssetsCurrent	330500000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	29200000	USD
CY2017Q1	us-gaap	Available For Sale Securities AvailableForSaleSecurities	27600000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2017Q1	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	29200000	USD
CY2017Q1	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	27600000	USD
CY2017Q1	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	25800000	USD
CY2016Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	29200000	USD
CY2017Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	27600000	USD
CY2017Q1	us-gaap	Available For Sale Securities Noncurrent AvailableForSaleSecuritiesNoncurrent	1800000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	86100000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	77900000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	94500000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	153500000	USD
CY2016Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-8200000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	59000000	USD
CY2017Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	181100000	USD
CY2016Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	32300000	USD
CY2017Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	108300000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	84900000	shares
CY2017Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	86600000	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	84600000	shares
CY2017Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	86300000	shares
CY2016Q4	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	100000	USD
CY2017Q1	us-gaap	Common Stock Value Outstanding CommonStockValueOutstanding	100000	USD
CY2016Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-19200000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-42000000	USD
CY2016Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	41100000	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	48200000	USD
CY2017Q1	us-gaap	Debt Instrument Term DebtInstrumentTerm	P6M
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	7300000	USD
CY2017Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8500000	USD
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	900000	USD
CY2017Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	1200000	USD
CY2016Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3400000	USD
CY2017Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3700000	USD
CY2016Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	0	USD
CY2017Q1	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-200000	USD
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	33400000	USD
CY2017Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	30100000	USD
CY2017Q1	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2016Q4	us-gaap	Goodwill Goodwill	11300000	USD
CY2017Q1	us-gaap	Goodwill Goodwill	11400000	USD
CY2016Q1	us-gaap	Gross Profit GrossProfit	75100000	USD
CY2017Q1	us-gaap	Gross Profit GrossProfit	94100000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19200000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-40300000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.23
CY2017Q1	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.49
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1400000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3700000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2100000	USD
CY2016Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6800000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-15800000	USD
CY2016Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-200000	USD
CY2017Q1	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	200000	USD
CY2016Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-8200000	USD
CY2017Q1	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-3300000	USD
CY2016Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10900000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1000000	USD
CY2016Q1	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	200000	USD
CY2017Q1	us-gaap	Increase Decrease In Other Deferred Liability IncreaseDecreaseInOtherDeferredLiability	1200000	USD
CY2016Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1000000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	7700000	USD
CY2016Q1	us-gaap	Interest Expense InterestExpense	100000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	500000	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	23000000	USD
CY2017Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	25300000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	45400000	USD
CY2017Q1	us-gaap	Inventory Net InventoryNet	46500000	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	20100000	USD
CY2017Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	17500000	USD
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2300000	USD
CY2017Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3700000	USD
CY2016Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	100000	USD
CY2017Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	200000	USD
CY2016Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	1900000	USD
CY2017Q1	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	2800000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	119000000	USD
CY2017Q1	us-gaap	Liabilities Liabilities	189400000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	402800000	USD
CY2017Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	467200000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	102400000	USD
CY2017Q1	us-gaap	Liabilities Current LiabilitiesCurrent	171700000	USD
CY2017Q1	us-gaap	Line Of Credit Facility Interest Rate At Period End LineOfCreditFacilityInterestRateAtPeriodEnd	0.032
CY2017Q1	us-gaap	Line Of Credit Facility Remaining Borrowing Capacity LineOfCreditFacilityRemainingBorrowingCapacity	125000000	USD
CY2016Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	0	USD
CY2017Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	75000000	USD
CY2017Q1	us-gaap	Litigation Reserve LitigationReserve	0	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3200000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	80300000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11200000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-21400000	USD
CY2016Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-200000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	300000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	-19200000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-41700000	USD
CY2016Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	5700000	USD
CY2017Q1	us-gaap	Noncash Or Part Noncash Acquisition Fixed Assets Acquired1 NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1	5600000	USD
CY2017Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	94300000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	134500000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-19200000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-40400000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	62500000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	11500000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	11200000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	10800000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	9900000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	12900000	USD
CY2017Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	6200000	USD
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	20000000	USD
CY2017Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	17900000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	2100000	USD
CY2017Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1900000	USD
CY2016Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2017Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2016Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2017Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-300000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	16600000	USD
CY2017Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	17700000	USD
CY2016Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	100000	USD
CY2017Q1	us-gaap	Other Noncash Expense OtherNoncashExpense	400000	USD
CY2016Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	400000	USD
CY2016Q4	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	2600000	USD
CY2017Q1	us-gaap	Other Sundry Liabilities Noncurrent OtherSundryLiabilitiesNoncurrent	2500000	USD
CY2017Q1	us-gaap	Payments For Proceeds From Tenant Allowance PaymentsForProceedsFromTenantAllowance	-3600000	USD
CY2016Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	10800000	USD
CY2017Q1	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	7400000	USD
CY2016Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	11500000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22900000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3800000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	5300000	USD
CY2017Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2017Q1	us-gaap	Preferred Stock Value Outstanding PreferredStockValueOutstanding	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9200000	USD
CY2017Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	17000000	USD
CY2017Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	75000000	USD
CY2016Q1	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	0	USD
CY2017Q1	us-gaap	Proceeds From Repayments Of Lines Of Credit ProceedsFromRepaymentsOfLinesOfCredit	75000000	USD
CY2016Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	11100000	USD
CY2017Q1	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	8900000	USD
CY2016Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	3800000	USD
CY2017Q1	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	4900000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	109400000	USD
CY2017Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	123400000	USD
CY2017Q1	us-gaap	Recorded Unconditional Purchase Obligation Due Within One Year RecordedUnconditionalPurchaseObligationDueWithinOneYear	61800000	USD
CY2016Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	600000	USD
CY2017Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	USD
CY2016Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	32200000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	48100000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-621000000	USD
CY2017Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-663300000	USD
CY2016Q1	us-gaap	Revenues Revenues	116200000	USD
CY2017Q1	us-gaap	Revenues Revenues	142300000	USD
CY2016Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	62100000	USD
CY2017Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	86400000	USD
CY2016Q1	us-gaap	Share Based Compensation ShareBasedCompensation	25100000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	30600000	USD
CY2015Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	3300000	USD
CY2016Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	5700000	USD
CY2016Q4	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	9800000	USD
CY2017Q1	us-gaap	Standard Product Warranty Accrual StandardProductWarrantyAccrual	9900000	USD
CY2016Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	283800000	USD
CY2017Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	277800000	USD
CY2016Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	82100000	shares
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	85200000	shares
CY2017Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:6px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with </font><font style="font-family:inherit;font-size:10pt;">U.S. GAAP</font><font style="font-family:inherit;font-size:10pt;"> requires us to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from these estimates. Significant estimates include excess or obsolete inventories, valuation of inventory, warranty accruals, employee bonus, clinical trial expenses, allowance for bad debt and refunds and rebates, including pharmacy rebates. </font></div></div>

Files In Submission

Name	View Source	Status
0001093557-17-000119-index-headers.html	Edgar Link	pending
0001093557-17-000119-index.html	Edgar Link	pending
0001093557-17-000119.txt	Edgar Link	pending
0001093557-17-000119-xbrl.zip	Edgar Link	pending
dxcm-20170331.xml	Edgar Link	completed
dxcm-20170331.xsd	Edgar Link	pending
dxcm-20170331_cal.xml	Edgar Link	unprocessable
dxcm-20170331_def.xml	Edgar Link	unprocessable
dxcm-20170331_lab.xml	Edgar Link	unprocessable
dxcm-20170331_pre.xml	Edgar Link	unprocessable
dxcm-33117x10q.htm	Edgar Link	pending
dxcm3312017exhibit3101.htm	Edgar Link	pending
dxcm3312017exhibit3102.htm	Edgar Link	pending
dxcm3312017exhibit3201.htm	Edgar Link	pending
dxcm3312017exhibit3202.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$DXCM
DEXCOM INC Stock $dxcm

2017 Q1 Form 10-Q Financial Statement

#000109355717000119 Filed on May 02, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM DEXCOM INC Stock $dxcm

2017 Q1 Form 10-Q Financial Statement

#000109355717000119 Filed on May 02, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$DXCM
DEXCOM INC Stock $dxcm